PMID- 34901229
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211215
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 8
DP  - 2021
TI  - Effect of Sodium Tanshinone IIA Sulfonate Injection on Blood Lipid in Patients 
      With Coronary Heart Disease: A Systematic Review and Meta-Analysis of Randomized 
      Clinical Trials.
PG  - 770746
LID - 10.3389/fcvm.2021.770746 [doi]
LID - 770746
AB  - Background: Lipid-lowering therapy is very important in secondary prevention of 
      coronary heart disease (CHD). In many clinical trials, it has been found that 
      Sodium Tanshinone IIA Sulfonate Injection (STS) have a lipid-lowering effect 
      while reducing major cardiovascular events in patients with CHD. However, up to 
      now, there is no system review on the effectiveness and safety of STS affecting 
      blood lipids. Purpose: The aim of this review is to systematically assess the 
      effects of STS on blood lipid levels in patients with CHD. Methods: Until Mar 
      2021, five databases (PubMed, EMBASE, Cochrane Library, China National Knowledge 
      Infrastructure, and Wanfang Database) were searched for randomized controlled 
      trials (RCTs) about STS treating patients with CHD. Risk bias was assessed for 
      included studies according to Cochrane handbook. The primary outcome was total 
      cholesterol (TC). The secondary outcomes were triglycerides (TG), low-density 
      lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), 
      and adverse events (AEs). Results: A total of 27 trials including 2,445 CHD 
      patients met the eligibility criteria. Most trials had high risks in random 
      sequence generation, allocation concealment, blinding of patients and personal, 
      blinding of outcome assessment. Meta-analysis showed that STS significantly 
      reduced plasma TC levels [MD = -1.34 mmol/l 95% CI (-1.59, -1.09), p < 0.00001, I 
      (2) = 98%], TG levels [MD = -0.49 mmol/l 95% CI (-0.62, -0.35), p < 0.00001, I 
      (2) = 97%], LDL-c levels [MD = -0.68 mmol/l (-0.80, -0.57), p < 0.00001, I (2) = 
      96%], increased HDL-c levels [MD = 0.26 mmol/l (0.15, 0.37), p < 0.00001, I (2) = 
      97%], without increasing the incidence of AEs [RR = 1.27 95% CI (0.72, 2.27), p = 
      0.94, I (2) = 0%] in patients with CHD. Conclusion: STS can safely and 
      effectively reduce plasma TC, TG and LDL-c levels in patients with CHD, and 
      improve plasma HDL-c levels. However, these findings require careful 
      recommendation due to the low overall quality of RCTs at present. More 
      multi-center, randomized, double-blind, placebo-controlled trials which are 
      designed follow the CONSORT 2010 guideline are needed.
CI  - Copyright (c) 2021 Zhou, Zhao, Peng, Han, Wang, Ren, Wang, Pan, Lin and Wang.
FAU - Zhou, Hufang
AU  - Zhou H
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Zhao, Ying
AU  - Zhao Y
AD  - Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
FAU - Peng, Wenhua
AU  - Peng W
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Han, Wenbo
AU  - Han W
AD  - Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.
FAU - Wang, Zichen
AU  - Wang Z
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Ren, Xiaoxia
AU  - Ren X
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Wang, Dayang
AU  - Wang D
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Pan, Guozhong
AU  - Pan G
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
FAU - Lin, Qian
AU  - Lin Q
AD  - Changping District Hospital of Integrated Traditional Chinese and Western 
      Medicine, Beijing, China.
FAU - Wang, Xian
AU  - Wang X
AD  - Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of 
      Chinese Medicine, Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20211124
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC8652084
OTO - NOTNLM
OT  - Sodium Tanshinone IIA Sulfonate
OT  - blood lipid
OT  - coronary heart disease
OT  - meta-analysis
OT  - randomized controlled trials
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2021/01/01
CRDT- 2021/12/13 18:10
PHST- 2021/09/04 00:00 [received]
PHST- 2021/11/03 00:00 [accepted]
PHST- 2021/12/13 18:10 [entrez]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2021.770746 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Nov 24;8:770746. doi: 10.3389/fcvm.2021.770746. 
      eCollection 2021.